Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

239
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
239
Positron Emission Tomography01:29

Positron Emission Tomography

5.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models.

Nature biotechnology·2026
Same author

Erasable FAP Targeted Spray-On Probe for Fluorescence-Guided Surgery.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Controlled Self-Immolative Release of β-Lapachone via an Optimized <i>para</i>-Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy.

Journal of the American Chemical Society·2025
Same author

Integrated Multi-Channel Automatic Cellular Profiling (iMAP) System for Cholangiocarcinoma Diagnosis.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Donor-dependent heterogeneity in therapeutic effects of adipose tissue extracellular vesicles.

Cell communication and signaling : CCS·2025
Same journal

Iron Single Atom Nanozyme-Mediated GPX4 Inhibitor Delivery for Self-Enhanced Ferroptosis.

Bioconjugate chemistry·2026
Same journal

SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy.

Bioconjugate chemistry·2026
Same journal

One-Pot Synthesis of Functionalized Coumarin Fluorophores Enables Rapid Access to Live-Cell Bioorthogonal Labeling and Microenvironmental Sensing Agents.

Bioconjugate chemistry·2026
Same journal

Enzymatic Synthesis of Glyco-DNA Equipped with Oligosaccharides and Charged Monosaccharides.

Bioconjugate chemistry·2026
Same journal

Electrochemical Tryptophan-Selective Bioconjugation in Neutral Buffer via Cooperative <i>N</i>-Oxyl Radicals.

Bioconjugate chemistry·2026
Same journal

Conjugates of Heme and Intrinsically Disordered Peptides toward the Development of Synthetic Artificial Oxygen Carriers.

Bioconjugate chemistry·2026
See all related articles

Related Experiment Video

Updated: Sep 18, 2025

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.5K

Fluorescent PSMA-Targeted Radiotheranostic Compounds for Multiscale Imaging.

G G Simpson1, J M Quintana1, J E Carrothers1

  • 1Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts MA 02115, United States.

Bioconjugate Chemistry
|June 27, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed fluorescent prostate-specific membrane antigen (PSMA) ligands to study their single-cell behavior. This work aids in understanding PSMA-targeted therapies and developing improved diagnostic and therapeutic agents.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.4K

Related Experiment Videos

Last Updated: Sep 18, 2025

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.4K

Area of Science:

  • Biomedical imaging
  • Radiopharmaceutical therapy
  • Molecular imaging

Background:

  • Prostate-specific membrane antigen (PSMA) is a key target for prostate cancer theranostics.
  • Understanding the cellular distribution of PSMA-targeting agents is crucial for optimizing theranostic probe development.
  • Current PSMA ligands lack detailed single-cell pharmacokinetic data.

Purpose of the Study:

  • To synthesize and characterize fluorescent analogs of PSMA-targeting ligands.
  • To enable detailed single-cell pharmacokinetic studies of PSMA-targeting agents.
  • To guide the development of next-generation theranostic probes for prostate cancer.

Main Methods:

  • Solid-phase synthesis of fluorescent PSMA analogs based on PSMA-617.
  • Optimization of the urea pharmacophore synthesis.
  • In vitro and in vivo evaluation of synthesized fluorescent ligands, including binding affinity and optical imaging properties.
  • Tissue and cellular biodistribution analysis using fluorescence imaging.

Main Results:

  • Two fluorescent PSMA ligands, PSMA-Lys-DOTA-Cy680 (3) and PSMA-Lys-DOTA-AF647 (4), were successfully synthesized.
  • These compounds exhibit PSMA binding affinities comparable to the parent compound.
  • The synthesized ligands demonstrate robust optical imaging properties and provide detailed biodistribution data.

Conclusions:

  • Fluorescent PSMA ligands can provide valuable insights into cellular pharmacokinetics.
  • This research facilitates microdosimetric and systemic modeling for improved radiopharmaceutical therapy design.
  • The developed fluorescent probes represent a significant advancement in PSMA-targeted theranostics.